Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down – Time to Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) gapped down prior to trading on Wednesday . The stock had previously closed at $34.65, but opened at $33.27. Collegium Pharmaceutical shares last traded at $34.3540, with a volume of 130,572 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on COLL shares. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Needham & Company LLC restated a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Finally, Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Collegium Pharmaceutical Stock Down 0.7%

The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The stock’s 50-day moving average price is $34.08 and its 200-day moving average price is $40.34. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of 16.87 and a beta of 0.74.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company had revenue of $193.52 million for the quarter, compared to the consensus estimate of $184.47 million. During the same quarter in the previous year, the company earned $1.49 EPS. Collegium Pharmaceutical’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 6.8 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of COLL. Group One Trading LLC acquired a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at $28,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 427 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares during the period. Kemnay Advisory Services Inc. acquired a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.